According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:
1. Novartis Ag (NYSE:NVS)
Novartis Ag (NYSE:NVS) is the #1 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year.
Learn more.
The Component Grade breakdown for Novartis Ag (NYSE:NVS) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: B.
Novartis Ag (NYSE:NVS) has a Due Diligence Score of 34, which is -10 points lower than the general drug manufacturer industry average of 44. Although this number is below the industry average, our proven quant model rates NVS as a "A".
NVS passed 12 out of 38 due diligence checks and has average fundamentals. Novartis Ag has seen its stock return 13.58% over the past year, overperforming other general drug manufacturer stocks by 27 percentage points.
2. Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ) is the #2 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year.
Learn more.
The Component Grade breakdown for Johnson & Johnson (NYSE:JNJ) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: A, Financials: B, and AI: B.
Johnson & Johnson (NYSE:JNJ) has a Due Diligence Score of 51, which is 7 points higher than the general drug manufacturer industry average of 44.
JNJ passed 18 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock return 4.31% over the past year, overperforming other general drug manufacturer stocks by 17 percentage points.
Johnson & Johnson has an average 1 year
price target of $163.60, an upside of 7.1% from Johnson & Johnson's current stock price of $152.75.
Johnson & Johnson stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Johnson & Johnson, 10% have issued a Strong Buy rating, 20% have issued a Buy, 70% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Grifols Sa (NASDAQ:GRFS)
Grifols Sa (NASDAQ:GRFS) is the #3 top general drug manufacturer stock out of 18 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year.
Learn more.
The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: B, Growth: B, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: B.
Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 32, which is -12 points lower than the general drug manufacturer industry average of 44. Although this number is below the industry average, our proven quant model rates GRFS as a "B".
GRFS passed 13 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 43.95% over the past year, overperforming other general drug manufacturer stocks by 57 percentage points.
Grifols Sa has an average 1 year
price target of $10.30, an upside of 13.94% from Grifols Sa's current stock price of $9.04.
Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.